Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 129.74% | 279.80% | 38.50% | 116.86% | 715.58% |
| Total Depreciation and Amortization | -23.74% | -44.74% | -50.02% | -25.95% | -33.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.07% | -36.24% | 180.65% | 175.51% | 168.92% |
| Change in Net Operating Assets | -151.91% | -48.13% | 91.19% | 4.23% | 62.47% |
| Cash from Operations | 62.75% | 178.16% | 1,267.39% | 396.20% | 238.98% |
| Capital Expenditure | -182.00% | -100.85% | -65.39% | -19.59% | 64.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -99.57% | -99.57% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.54% | -69.37% | -292.67% | -367.74% | -2,761.78% |
| Cash from Investing | 64.26% | -70.74% | -469.02% | -462.05% | -297.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -30.06% | -71.16% | -78.76% | -91.76% | -84.08% |
| Repurchase of Common Stock | -159.12% | -158.69% | -158.60% | -158.60% | -619.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -67.78% | -116.66% | -113.10% | -98.13% | -86.68% |
| Foreign Exchange rate Adjustments | 162.45% | 8,325.00% | 431.65% | -807.46% | -193.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,224.85% | 2,470.76% | -88.50% | -123.02% | -106.85% |